Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5873456 | 1.00 | HDAC1 (0.57) | HDAC1HDAC2HDAC3NCOR2MAOA | |
| SCHEMBL15816134 | 1.00 | HDAC1 (0.57) | HDAC1HDAC2HDAC3NCOR2MAOA | |
| SCHEMBL6438248 | 0.81 | HDAC1 (0.44) | HDAC1HDAC2HDAC3NCOR2MAOA | |
| SCHEMBL6438252 | 0.81 | HDAC1 (0.44) | HDAC1HDAC2HDAC3NCOR2MAOA | |
| SCHEMBL6438249 | 0.81 | HDAC1 (0.44) | HDAC1HDAC2HDAC3NCOR2MAOA | |
| SCHEMBL24376117 | 0.80 | HDAC1 (0.57) | HDAC1HDAC2HDAC3NCOR2MAOA | |
| SCHEMBL6027480 | 0.80 | ATM (0.48) | HDAC1HDAC2HDAC3NCOR2MAOA | |
| SCHEMBL515423 | 0.80 | ATM (0.48) | HDAC1HDAC2HDAC3NCOR2MAOA | |
| SCHEMBL515424 | 0.80 | ATM (0.48) | HDAC1HDAC2HDAC3NCOR2MAOA | |
| SCHEMBL7035017 | 0.78 | HDAC1 (0.55) | HDAC1HDAC2HDAC3NCOR2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989052-B1 | Phase change ink printing process | XEROX CORPORATION (US) | 2006-01-24 | — | — | US | claimed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | claimed |
| US-9175041-B2 | Crystal structures of dolastatin 16, dolamethylleuine and dolaphenvaline, and methods for preparing dolamethylleuine and dolaphenvaline | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140286943-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | AUSPEX PHARMACEUTICALS INC (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140179897-A1 | CRYSTAL STRUCTURES OF DOLASTATIN 16, DOLAMETHYLLEUINE AND DOLAPHENVALINE, AND METHODS FOR PREPARING DOLAMETHYLLEUINE AND DOLAPHENVALINE | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY | 2014-06-26 | — | — | US | disclosed |
| US-6989052-B1 | Phase change ink printing process | XEROX CORPORATION (US) | 2006-01-24 | — | — | US | disclosed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | disclosed |
| US-4756840-A | Enhancing aroma of consumable product | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1988-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179897-A1 | CRYSTAL STRUCTURES OF DOLASTATIN 16, DOLAMETHYLLEUINE AND DOLAPHENVALINE, AND METHODS FOR PREPARING DOLAMETHYLLEUINE AND DOLAPHENVALINE | DDOST, DAD1, ALG8 | HDAC1 3033/4885HDAC2 3922/4885HDAC3 4679/4885 |
| US-20140286943-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | P2RY12, P2RY11, P2RY2 | HDAC1 4706/4885HDAC2 4082/4885HDAC3 3606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.